Second-Generation Stat5 Inhibitors to Fight Prostate Cancer
Official title: Second-Generation Stat5 Inhibitors for Prostate Cancer Therapy
Funded at Thomas Jefferson University · NIH-11448592 · Data updated 2026-11-12
A new drug candidate is being developed to block Stat5 signaling in prostate cancer that has stopped responding to standard hormone therapy.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Thomas Jefferson University NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | July 17, 2026 |
| Project end | June 30, 2031 |
| Funding year | 2026 |
| Award (this year) | $796,727 |
| NIH project number | 1R01CA308805-01A1 |
| Project ID | NIH-11448592 on NIH RePORTER |
Who could benefit from this research
✓Could help
Men with advanced prostate cancer characterized by AR-driven disease, particularly castration-resistant forms.
✕Less likely to help
Patients whose tumors do not depend on Stat5 signaling or cannot tolerate the drug could see no benefit.
What this research studies
This project aims to create orally available Stat5 inhibitors to slow or stop the growth of prostate cancers that rely on androgen receptor signaling. Researchers will optimize lead compounds to improve stability, absorption, and solubility while confirming how they block Stat5 and reduce AR levels in cancer cells. The work uses laboratory models and will examine how the drugs behave in cells and animal systems to inform future clinical development. If successful, these Stat5 inhibitors could become a new treatment option for patients with castration-resistant prostate cancer.
Why it matters
Potential benefit: If successful, patients with CRPC may receive a new oral therapy that reduces tumor growth by lowering AR levels.
How similar studies have gone: Previous research supports Stat5 as a driver of prostate cancer cell survival and responses to SH2-domain inhibition in preclinical models.
Where this research is happening
-
Thomas Jefferson University
Philadelphia, United States Active
Researchers
- Principal investigator: Nevalainen, Marja T — Thomas Jefferson University
- Study coordinator: Nevalainen, Marja T
Related research
Other NIH-funded projects on the same topics.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
-
Characterizing epigenetic targets in prostate cancer to help AR-driven cancer
A research project at MD Anderson aims to understand how epigenetic factors shape androgen receptor signaling in prostate cancer to find new ways to treat resistant forms of the disease.
-
AR and RNA-binding in prostate cancer resistance
A cancer research grant exploring how the androgen receptor’s interaction with RNA may drive treatment resistance in prostate cancer, with potential to guide new therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.